Baron Funds Comments on Illumina Inc.

Author's Avatar
Holly LaFon
May 12, 2014
Article's Main Image

Shares of Illumina, Inc. (

ILMN, Financial), the leading provider of next generation DNA sequencing instruments and consumables, rose during the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)

From Baron Funds' first quarter 2014 letter to shareholders.

Also check out:
Rating:
0 / 5 (0 votes)

Please Login to leave a comment

Please Login to leave a comment

Author's Avatar
I'm a financial journalist with a Master of Science in journalism from Medill at Northwestern University.